Prognosis
Rapid Covid-Testing Firm Draws $60 Million From Ventura Capital
- Imperial College professor retools nutrition tech to virus
- Investment will help ramp up manufacturing, broaden offering
This article is for subscribers only.
DNANudge Ltd., a maker of rapid Covid tests that were adapted on the fly from a consumer dietary-guidance technology, has received $60 million in funding led by Ventura Capital in a bid to ramp up production and expand diagnostic applications.
DNANudge will use the funding, which includes participation by Bank Julius Baer, to make more cartridges for its portable devices, which can diagnose Covid in about an hour, founder Christofer Toumazou said in an interview. The company is also making cartridges for cancer testing and consumer skin-care products.